Oncternal Therapeutics Inc ONCT:NASDAQ

Last Price$1.20Cboe Real-Time Last Sale as of 2:47PM ET 8/15/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.04(3.45%)
Bid (Size)$1.17 (500)
Ask (Size)$1.20 (154)
Day Low / High$1.17 - 1.24
Volume551.3 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/15/2022

 

Oncternal Therapeutics Inc ( NASDAQ )

Price: $1.20
Change: +0.04 (3.45%)
Volume: 551.3 K
2:47PM ET 8/15/2022
 
 

Beyondspring Inc ( NASDAQ )

Price: $1.65
Change: +0.06 (3.77%)
Volume: 107.0 K
2:52PM ET 8/15/2022
 
 

Lipocine Inc ( NASDAQ )

Price: $0.72
Change: +0.01 (2.08%)
Volume: 196.4 K
11:58AM ET 8/15/2022
 
 

Tonix Pharmaceuticals Holding Corp ( NASDAQ )

Price: $1.59
Change: +0.19 (13.21%)
Volume: 6.9 M
2:49PM ET 8/15/2022
 
 

Zynerba Pharmaceuticals Inc ( NASDAQ )

Price: $1.37
Change: +0.05 (4.20%)
Volume: 401.4 K
2:26PM ET 8/15/2022
 

Read more news Recent News

Oncternal Therapeutics to Work With AbbVie Unit On Mantle Cell Lymphoma Clinical Trial; Shares Rise After Hours
4:24PM ET 7/14/2022 MT Newswires

Oncternal Therapeutics (ONCT) said late Thursday it entered into a collaboration with AbbVie's (ABBV) Pharmacyclics unit that includes supply of ibrutinib...

--Maxim Initiates Oncternal Therapeutics at Buy, Sets Price Target at $3.50
10:45AM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Oncternal Therapeutics Shifts Priority to Zilovertamab From ONCT-216; Shares Fall
10:02AM ET 4/13/2022 MT Newswires

Oncternal Therapeutics (ONCT) said Wednesday that it has deprioritized the development of ONCT-216 to reallocate resources to zilovertamab, which is...

-- Earnings Flash (ONCT) ONCTERNAL THERAPEUTICS Reports Q4 Loss $-0.16, vs. Street Est of $-0.25
4:03PM ET 3/10/2022 MT Newswires

...

Company Profile

Business DescriptionOncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA. View company web site for more details
Address12230 El Camino Real
San Diego, California 92130
Phone+1.858.434.1113
Number of Employees21
Recent SEC Filing08/09/20228-K
President, Chief Executive Officer & DirectorJames B. Breitmeyer
Chief Financial Officer, Secretary & TreasurerRichard Glenn Vincent
Chief Scientific OfficerGunnar F. Kaufmann
Chief Technology OfficerRajesh Krishnan

Company Highlights

Price Open$1.17
Previous Close$1.16
52 Week Range$0.69 - 4.63
Market Capitalization$63.9 M
Shares Outstanding53.2 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.79
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-1,086.66%
Return on Equity-46.73%

Analyst Ratings as of 05/09/2022

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset